| Schedule of Disaggregation of Revenue |
The Company’s revenues disaggregated by product category and geography for the three and six months ended June 30, 2026 and June 30, 2025 were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
June 30, |
|
|
|
United States |
|
|
International |
|
|
Total |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Glaucoma |
|
$ |
118,549 |
|
|
$ |
72,282 |
|
|
$ |
36,631 |
|
|
$ |
31,251 |
|
|
$ |
155,180 |
|
|
$ |
103,533 |
|
Corneal Health |
|
|
28,190 |
|
|
|
18,237 |
|
|
|
2,240 |
|
|
|
2,350 |
|
|
|
30,430 |
|
|
|
20,587 |
|
Total |
|
$ |
146,739 |
|
|
$ |
90,519 |
|
|
$ |
38,871 |
|
|
$ |
33,601 |
|
|
$ |
185,610 |
|
|
$ |
124,120 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
|
June 30, |
|
|
|
United States |
|
|
International |
|
|
Total |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Glaucoma |
|
$ |
212,002 |
|
|
$ |
131,410 |
|
|
$ |
72,438 |
|
|
$ |
60,260 |
|
|
$ |
284,440 |
|
|
$ |
191,670 |
|
Corneal Health |
|
|
47,081 |
|
|
|
34,179 |
|
|
|
4,660 |
|
|
|
4,935 |
|
|
|
51,741 |
|
|
|
39,114 |
|
Total |
|
$ |
259,083 |
|
|
$ |
165,589 |
|
|
$ |
77,098 |
|
|
$ |
65,195 |
|
|
$ |
336,181 |
|
|
$ |
230,784 |
|
|
| Schedule of Accrued Sale Rebate Liability Activity |
|
|
|
|
|
|
|
June 30, |
|
|
|
2026 |
|
Reserve balance, December 31, 2025 |
|
$ |
10,192 |
|
Current period provision |
|
|
9,790 |
|
Payments and credits |
|
|
(5,611 |
) |
Reserve balance, June 30, 2026 |
|
$ |
14,371 |
|
|